Green Thumb Industries
Market Cap
CA$4.4b
Last Updated
2020/08/12 23:52 UTC
Data Sources
Company Financials +
Executive Summary
Green Thumb Industries Inc. manufactures, distributes, and sells various cannabis products for medical and adult-use in the United States.
Rewards
Risk Analysis
Snowflake Analysis
High growth potential and slightly overvalued.
Similar Companies
Share Price & News
How has Green Thumb Industries's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GTII's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
7.2%
GTII
2.5%
CA Pharmaceuticals
0.9%
CA Market
1 Year Return
69.8%
GTII
-43.4%
CA Pharmaceuticals
-1.2%
CA Market
Return vs Industry: GTII exceeded the Canadian Pharmaceuticals industry which returned -48.7% over the past year.
Return vs Market: GTII exceeded the Canadian Market which returned -2.7% over the past year.
Shareholder returns
| GTII | Industry | Market | |
|---|---|---|---|
| 7 Day | 7.2% | 2.5% | 0.9% |
| 30 Day | 27.9% | 9.2% | 6.3% |
| 90 Day | 78.0% | 26.5% | 15.3% |
| 1 Year | 69.8%69.8% | -43.4%-43.4% | 2.2%-1.2% |
| 3 Year | n/a | 5.3%4.4% | 13.2%2.4% |
| 5 Year | n/a | 307.4%307.4% | 38.9%17.8% |
Price Volatility Vs. Market
How volatile is Green Thumb Industries's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Investors Who Bought Green Thumb Industries (CSE:GTII) Shares A Year Ago Are Now Up 47%3 months ago | Simply Wall St
Have Green Thumb Industries Inc. (CSE:GTII) Insiders Been Selling Their Stock?3 months ago | Simply Wall St
How Many Green Thumb Industries Inc. (CSE:GTII) Shares Have Insiders Sold, In The Last Year?Valuation
Is Green Thumb Industries undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GTII (CA$19.76) is trading below our estimate of fair value (CA$120.61)
Significantly Below Fair Value: GTII is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: GTII is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.
PE vs Market: GTII is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GTII's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GTII is overvalued based on its PB Ratio (3.6x) compared to the CA Pharmaceuticals industry average (1.5x).
Next Steps
Future Growth
How is Green Thumb Industries forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
74.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GTII is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: GTII is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: GTII's is expected to become profitable in the next 3 years.
Revenue vs Market: GTII's revenue (28.2% per year) is forecast to grow faster than the Canadian market (6.1% per year).
High Growth Revenue: GTII's revenue (28.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GTII's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Green Thumb Industries performed over the past 5 years?
-89.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GTII is currently unprofitable.
Growing Profit Margin: GTII is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GTII is unprofitable, and losses have increased over the past 5 years at a rate of 89.2% per year.
Accelerating Growth: Unable to compare GTII's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GTII is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-12.4%).
Return on Equity
High ROE: GTII has a negative Return on Equity (-6.29%), as it is currently unprofitable.
Next Steps
Financial Health
How is Green Thumb Industries's financial position?
Financial Position Analysis
Short Term Liabilities: GTII's short term assets ($140.8M) exceed its short term liabilities ($128.3M).
Long Term Liabilities: GTII's short term assets ($140.8M) do not cover its long term liabilities ($242.0M).
Debt to Equity History and Analysis
Debt Level: GTII's debt to equity ratio (10.9%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if GTII's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GTII has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if GTII has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Green Thumb Industries's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GTII's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GTII's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GTII's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GTII's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GTII's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
0.8yrs
Average management tenure
CEO
Ben Kovler (41 yo)
2yrs
Tenure
US$3,915,943
Compensation
Mr. Benjamin Kovler, also known as Ben, serves as Chairman at Green Thumb Industries Inc. and has been its Director since 2014. He is Founder of Green Thumb Industries Inc. He also serves as CEO at Green T ...
CEO Compensation Analysis
Compensation vs Market: Ben's total compensation ($USD3.92M) is about average for companies of similar size in the Canadian market ($USD3.12M).
Compensation vs Earnings: Ben's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 2yrs | US$3.92m | 8.31% $ 364.7m | |
| CFO & Director | 3.08yrs | US$3.57m | 2.03% $ 89.2m | |
| Chief Strategy Officer | no data | US$1.88m | 0.22% $ 9.8m | |
| MD of Integral Associates & Director | 1.17yrs | US$227.74k | 1.91% $ 84.0m | |
| Chief Accounting Officer | no data | no data | no data | |
| Chief Information Officer | 0.17yr | no data | no data | |
| General Counsel & Secretary | 0.75yr | no data | 0.021% $ 918.7k | |
| Vice President of Communications | no data | no data | no data | |
| Senior VP of National Sales | no data | no data | no data | |
| Senior Vice President of Marketing | 1.58yrs | no data | no data | |
| Chief People Officer | no data | no data | 0.022% $ 988.1k | |
| Head of Capital Markets | 0.42yr | US$322.98k | 1.28% $ 56.3m |
0.8yrs
Average Tenure
48yo
Average Age
Experienced Management: GTII's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 2yrs | US$3.92m | 8.31% $ 364.7m | |
| CFO & Director | 3.08yrs | US$3.57m | 2.03% $ 89.2m | |
| MD of Integral Associates & Director | 1.17yrs | US$227.74k | 1.91% $ 84.0m | |
| Independent Non Executive Director | 2.17yrs | US$50.00k | 0.096% $ 4.2m | |
| Independent Non Executive Director | 1.33yrs | US$268.29k | 0.0098% $ 431.7k | |
| Independent Non Executive Director | 2.08yrs | US$50.00k | 0.034% $ 1.5m | |
| Non Executive Director | 5.5yrs | US$50.00k | 0.92% $ 40.3m |
2.2yrs
Average Tenure
54yo
Average Age
Experienced Board: GTII's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.9%.
Top Shareholders
Company Information
Green Thumb Industries Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Green Thumb Industries Inc.
- Ticker: GTII
- Exchange: CNSX
- Founded: 2014
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$4.392b
- Shares outstanding: 222.25m
- Website: https://www.gtigrows.com
Number of Employees
Location
- Green Thumb Industries Inc.
- 325 West Huron Street
- Suite 412
- Chicago
- Illinois
- 60654
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| GTBI.F | OTCPK (Pink Sheets LLC) | Yes | Subordinate Voting Shares | US | USD | Jun 2018 |
| R9U2 | DB (Deutsche Boerse AG) | Yes | Subordinate Voting Shares | DE | EUR | Jun 2018 |
| GTII | CNSX (Canadian National Stock Exchange) | Yes | Subordinate Voting Shares | CA | CAD | Jun 2018 |
Biography
Green Thumb Industries Inc. manufactures, distributes, and sells various cannabis products for medical and adult-use in the United States. It offers cannabis flower; and processed and packaged products, in ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/08/12 23:52 |
| End of Day Share Price | 2020/08/12 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.